Combined Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor/ Anti-VEGF Antibody, and Anti-PD-1/ PD-L1 Antibody as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Bevacizumab (Primary) ; Camrelizumab (Primary) ; Donafenib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Regorafenib (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary) ; Sorafenib (Primary) ; Tislelizumab (Primary) ; Toripalimab (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms HAIC-TKI-ICI

01 Jun 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.
14 Feb 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com